Effect of rifampicin on the pharmacokinetics of pioglitazone
暂无分享,去创建一个
[1] P. Neuvonen,et al. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. , 2005, Basic & clinical pharmacology & toxicology.
[2] P. Neuvonen,et al. Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone , 2005, Clinical pharmacology and therapeutics.
[3] H. Glaeser,et al. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. , 2005, British journal of clinical pharmacology.
[4] P. Neuvonen,et al. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone , 2004, Clinical pharmacology and therapeutics.
[5] K. Brøsen,et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.
[6] S. Kim,et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in korean healthy subjects , 2004 .
[7] Ji-Young Park,et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide , 2003, Clinical pharmacology and therapeutics.
[8] P. Neuvonen,et al. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide , 2003, Clinical pharmacology and therapeutics.
[9] Liang-Shang Gan,et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[10] R. Franklin,et al. Identification of novel metabolites of pioglitazone in rat and dog , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[11] P. Neuvonen,et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[12] S. Strom,et al. Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes , 2002, Journal of Pharmacology and Experimental Therapeutics.
[13] M. Hanefeld,et al. Pharmacokinetics and clinical efficacy of pioglitazone. , 2001, International journal of clinical practice. Supplement.
[14] P. Neuvonen,et al. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide , 2001, Clinical pharmacology and therapeutics.
[15] S. Baba,et al. Pioglitazone: A Review of Japanese Clinical Studies , 2001, Current medical research and opinion.
[16] M. Danhof,et al. Clinical pharmacokinetics of pioglitazone , 2000 .
[17] P. Neuvonen,et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations , 2000, Clinical pharmacology and therapeutics.
[18] P. Neuvonen,et al. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. , 2000, British journal of clinical pharmacology.
[19] P. Neuvonen,et al. Rifampin decreases the plasma concentrations and effects of repaglinide , 2000, Clinical pharmacology and therapeutics.
[20] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[21] P. Neuvonen,et al. Triazolam is ineffective in patients taking rifampin , 1997, Clinical pharmacology and therapeutics.
[22] M. Fromm,et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.
[23] M. Fromm,et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[24] P. Neuvonen,et al. Rifampin drastically reduces plasma concentrations and effects of oral midazolam , 1996, Clinical pharmacology and therapeutics.
[25] J. Pascussi,et al. INDUCTION OF CYP 2 C GENES IN HUMAN HEPATOCYTES IN PRIMARY CULTURE , 2001 .